Sapan Shah, Ph.D.
Dr. Shah is Founder and CEO of Novatherx, a life science company providing expertise, leadership and investment support to biotech and pharmaceutical companies advancing innovative therapeutics that address areas of critical unmet medical need.
Over the past 20 years, Dr. Shah has worked to advance products and lead companies in the life sciences area. He was previously President and CEO of ARMGO Pharma, a biotechnology company launched from Columbia University developing novel small-molecule therapeutics to treat debilitating cardiac and rare muscle diseases. Dr. Shah also served as President and CEO of Shionogi, Inc., where he expanded the US pharmaceutical business of Shionogi & Co., Ltd., growing from its inception as a small clinical development subsidiary to ultimately a fully integrated commercial entity with $400M in sales and over 400 employees. At Shionogi he also led efforts to negotiate, structure, launch, and operate a highly successful joint venture between Shionogi and GSK/ ViiV, resulting in the discovery, development and commercialization of a novel HIV integrase inhibitor. In addition, Dr. Shah was also previously co-founder and Chairman of Ezose Sciences, a high throughput glycomics company launched out of Hokkaido University pioneering novel techniques for glycoprotein biomarker discovery.
Dr. Shah began his career at McKinsey & Company, advising pharmaceutical and biotech clients on a wide range of R&D, commercial and corporate strategy matters. He earned his Ph.D. degree in Molecular Biophysics and Biochemistry from Yale University and holds BA degrees in Mathematics and Biochemistry from the Integrated Science Program at Northwestern University.